Delandistrogene Moxeparvovec Shows Sustained Functional Benefits Three Years After Gene Therapy
A three-year follow-up of the phase 3 EMBARK trial indicates that delandistrogene moxeparvovec provides sustained functional benefits and slows disease ...

